D
David J. MacEwan
Researcher at University of Liverpool
Publications - 113
Citations - 7631
David J. MacEwan is an academic researcher from University of Liverpool. The author has contributed to research in topics: Tumor necrosis factor alpha & Protein kinase C. The author has an hindex of 38, co-authored 110 publications receiving 6659 citations. Previous affiliations of David J. MacEwan include University of Aberdeen & University of Glasgow.
Papers
More filters
Journal ArticleDOI
Experimental design and analysis and their reporting II: updated and simplified guidance for authors and peer reviewers
Michael J. Curtis,Steve Alexander,Giuseppe Cirino,James R. Docherty,Christopher H. George,Mark A. Giembycz,Daniel Hoyer,Daniel Hoyer,Paul A. Insel,Angelo A. Izzo,Yong Ji,David J. MacEwan,Christopher G. Sobey,S. Clare Stanford,Mauro M. Teixeira,Susan Wonnacott,Amrita Ahluwalia +16 more
TL;DR: The guidelines have been simplified for ease of understanding by authors, to make it more straightforward for peer reviewers to check compliance and to facilitate the curation of the journal's efforts to improve standards.
Journal ArticleDOI
Experimental design and analysis and their reporting: new guidance for publication in BJP.
Michael J. Curtis,Richard A. Bond,Domenico Spina,Amrita Ahluwalia,Stephen P A Alexander,Mark A. Giembycz,Annette Gilchrist,Daniel Hoyer,Paul A. Insel,Angelo A. Izzo,Andrew J Lawrence,David J. MacEwan,Lawrence D. F. Moon,Susan Wonnacott,Arthur H. Weston,John C. McGrath +15 more
TL;DR: In this article, the authors present a series of linked editorials in the context of biomedical journal abstracts, including: http://onlinelibrary.wiley.com/doi/10.1111/bph.12954/abstract, http://Onlinelabel. wiley. com/doi /10.12956/ABstract, https://www.wired.org/content/index.cfm/
Journal ArticleDOI
TNF receptor subtype signalling: differences and cellular consequences.
TL;DR: This review addresses the structural basis of TNF signalling, the pathways employed with their cellular consequences, and focuses on the specific role played by each of the two TNF receptor isotypes, TNFR1 and TNFR2.
Journal ArticleDOI
Goals and practicalities of immunoblotting and immunohistochemistry: A guide for submission to the British Journal of Pharmacology.
Stephen P.H. Alexander,Richard E. Roberts,Brad R.S. Broughton,Christopher G. Sobey,Christopher H. George,S. Clare Stanford,Giuseppe Cirino,James R. Docherty,Mark A. Giembycz,Daniel Hoyer,Paul A. Insel,Angelo A. Izzo,Yong Ji,David J. MacEwan,Jonathan E. Mangum,Susan Wonnacott,Amrita Ahluwalia +16 more
TL;DR: The aim of this article is to outline the rationale for, and the expectations of, the BJP with respect to work published in the Journal that includes immunoblotting or immunohistochemical data and to reduce potential misinterpretations and to maximise the communication and transparency of essential information.
Journal ArticleDOI
TNF ligands and receptors – a matter of life and death
TL;DR: It is only through its quirky tumour-killing characteristic that TNF cytokine was first identified and may still hold the key to effective tumour therapy and the majority of information has been gained about TNF.